[Role of toll-like receptors in respiratory diseases]

Targeting mast cells: Uncovering prolific therapeutic role in myriad diseases

The mast cells are integral part of immune system and they have pleiotropic physiological functions in our body. Any type of abnormal stimuli causes the mast cells receptors to spur the otherwise innocuous mast cells to degranulate and release inflammatory mediators like histamine, cytokines, chemokines and prostaglandins. These mediators are involved in various diseases like allergy, asthma, mastocytosis, cardiovascular disorders, etc. Herein, we describe the receptors involved in degranulation of mast cells and are broadly divided into four categories: G-protein coupled receptors, ligand gated ion channels, immunoreceptors and pattern recognition receptors. Although, activation of pattern recognition receptors do not cause mast cell degranulation, but result in cytokines production. Degranulation itself is a complex process involving cascade of events like membrane fusion events and various proteins like VAMP, Syntaxins, DOCK5, SNAP-23, MARCKS. Furthermore, we described these mast cell receptors antagonists or agonists useful in treatment of myriad diseases. Like, omalizumab anti-IgE antibody is highly effective in asthma, allergic disorders treatment and recently mechanistic insight of IgE uncovered; matrix mettaloprotease inhibitor marimistat is under phase III trial for inflammation, muscular dystrophy diseases; ZPL-389 (H4 receptor antagonist) is in Phase 2a Clinical Trial for atopic dermatitis and psoriasis; JNJ3851868 an oral H4 receptor antagonist is in phase II clinical development for asthma, rheumatoid arthritis. Therefore, research is still in inchoate stage to uncover mast cell biology, mast cell receptors, their therapeutic role in myriad diseases.

Linking Endotoxins, African Dust PM10 and Asthma in an Urban and Rural Environment of Puerto Rico

African Dust Events (ADE) are a seasonal phenomenon that has been suggested to exacerbate respiratory and proinflammatory diseases in Puerto Rico (PR). Increases in PM₁₀ concentration and the effects of biological endotoxins (ENX) are critical factors to consider during these storms. ENX promote proinflammatory responses in lungs of susceptible individuals through activation of the Toll-like receptors (TLR2/4) signaling pathways. The objective of the study was to evaluate the toxicological and proinflammatory responses stimulated by ADE PM₁₀ ENX reaching PR using human bronchial epithelial cells. PM₁₀ organic extracts from a rural and urban site in PR (March 2004) were obtained from ADE and non-ADE and compared. A retrospective data analysis (PM₁₀ concentration, aerosol images, and pediatric asthma claims) was performed from 2000 to 2012 with particular emphasis in 2004 to classify PM samples. Urban extracts were highly toxic, proinflammatory (IL-6/IL-8 secretion), and induced higher TLR4 expression and NF-κB activation compared to rural extracts. ENX were found to contribute to cytotoxicity and inflammatory responses provoked by urban ADE PM₁₀ exposure suggesting a synergistic potency of local and natural ENX incoming from ADE. The contribution of ADE PM₁₀ ENX is valuable in order to understand interactions and action mechanisms of airborne pollutants as asthma triggers in PR.

Effect of different 1, 25-(OH)2D3 doses on high mobility group box1 and toll-like receptors 4 expression in lung tissue of asthmatic mice

We established a mouse model of asthmatic airway remodeling. To investigate the effects of different doses of 1,2 5-(OH)2D3 on airway remodeling, expression of high mobility group box 1 (HMGB1) and Toll-like receptors 4 (TLR4) in asthmatic mice. The female mice (BALB/c) groups consisted of a control group, asthma group and 1,2 5-(OH)2D3 low, middle, high dose group. Each group contained 10 mice. An asthmatic mice model was induced by ovalbumin. The control group and asthma group used physiological saline instead. 1,2 5-(OH)2D3 low, middle and high dose group was given different doses of 1,2 5-(OH)2D3 respectively. Changes in mice airway structure were observed by hematoxylin-eosin (H&E). The expression of HMGB1 and TLR4 in molecular lever were monitored by RT-PCR. We used immunohistochemistry to test HMGB1 and TLR4 protein levels. Obvious changes were noted in the airway of OVA-induced asthma mice compared with the control group by HE. These changes were less pronounced in mice receiving the low and middle doses of 1,2 5-(OH)2D3, but were more pronounced in mice receiving the highest dose of 1,2 5-(OH)2D3. Immunohistochemistry showed that expression of HMGB1 and TLR4 in the asthma group was higher than the control group. And low and middle dose group was decreased compared with asthma group, while higher than the control group; high dose group had an increased expression compared with the asthma group. From RT-PCR we got the same results as immunohistochemistry. In the asthmatic airway remodeling animal model, the appropriate amount of 1,2 5-(OH)2D3 reduced airway remodeling in asthmatic mice, and decreased the expression of HMGB1 and TLR4 in the asthmatic mice. However, over dose might play detrimental effect.

[Role of inflammation in the etiopathogenesis of COPD]

Inflammation is one of the first immune system responses to any type of aggression. As with any type of aggression, the lesion produced by inhalation of tobacco smoke prompts an innate inflammatory response. Subsequently, this lesion is stimulated by the release of various chemical factors that enhance the inflammatory response and, finally--depending on the type of aggression--acquired immunity is activated, which, mediated by lymphocyte participation, serves to establish a physical barrier against the propagation of the lesion and to aid repair of the damaged pulmonary tissue. However, the balance between inflammation and repair is not always maintained, as is the case in chronic obstructive pulmonary disease (COPD), in which marked changes appear in the architecture of the airways, alveolar spaces and pulmonary arteries, forming the structural background of the functional changes characteristic of this disease. COPD is basically a pulmonary disease but data are available on the existence of associated systemic inflammation. The origins of this systemic inflammation are unclear: some information indicates that tobacco smoke is a direct origin common to local and systemic inflammation, while other data point to primary pulmonary inflammation that secondarily produces systemic involvement. The present review describes the main mechanisms involved in both pulmonary and systemic inflammation in COPD.